Aspirin

In a new analysis of the COMPASS trial, rivaroxaban plus aspirin outperformed aspirin alone in overall and CV mortality among patients with chronic CAD or peripheral artery disease.

Clopidogrel or aspirin monotherapy after 6 to 18 months of dual antiplatelet therapy following PCI.

Aspirin 81 mg daily vs. 325 mg daily for secondary CVD prevention.

Stefan Holubar, MD, MS, Cleveland Clinic, told Healio low-dose aspirin VTE extended prophylaxis following inflammatory bowel disease surgery was safe and cost-effective compared with enoxaparin or no prophylaxis.

Rivaroxaban plus low-dose aspirin reduced incidence of total severe CV and other adverse events in patients with peripheral artery disease who had lower-extremity revascularization, according to new data from the VOYAGER PAD trial.

In patients who underwent PCI with a drug-eluting stent and took dual antiplatelet therapy for 6 to 18 months, subsequent clopidogrel monotherapy was superior to aspirin monotherapy, according to data from the HOST-EXAM trial.

Among patients with atherosclerotic CVD, there was no difference in CV events or major bleeding according to aspirin dose, researchers reported at the American College of Cardiology Scientific Session.

The 2021 American College of Cardiology Scientific Session will be held virtually from May 15 through 17 and will feature 25 late-breaking clinical trials, 17 featured clinical research presentations and numerous abstract presentations.

Nearly one-third of patients with atrial fibrillation and/or venous thromboembolism treated with a direct oral anticoagulant, or DOAC, were also using aspirin without clear indications, researchers reported.

Low-dose aspirin suppressed the recurrence of colorectal polyps in patients with familial adenomatous polyposis, according to research in The Lancet.